Laurion Capital Management LP Nektar Therapeutics Transaction History

Laurion Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.53 - $1.03 $44,914 - $87,286	84,744 New	84,744 $49,000
Q2 2022 Aug 15, 2022	SELL	$3.17 - $6.17 $317,000 - $617,000	-100,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.16 - $13.72 $416,000 - $1.37 Million	100,000 New	100,000 $539,000
Q3 2020 Nov 13, 2020	SELL	$16.59 - $24.79 $172,552 - $257,840	-10,401 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$16.86 - $23.44 $175,360 - $243,799	10,401 New	10,401 $241,000

Q1 2019 May 08, 2019	SELL	$31.58 - $46.35 $295,430 - $433,604	-9,355 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$30.43 - $56.65 $175,520 - $326,757	5,768 Added 160.8%	9,355 $308,000
Q3 2018 Nov 13, 2018	BUY	$46.46 - $68.49 $166,652 - $245,673	3,587 New	3,587 $219,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $242M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.